Skip to content
Screener

Neuropace, Inc. NPCE Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$27.4MBeat by $2.3M
EPS-$0.11Beat by $0.09
Revenue estimate$25.0M
EPS estimate-$0.20

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$27.1M
EPS estimate-$0.11

Financials

Q3 2025

Income statement

See full
Revenue$27.4M+29.9%
Gross profit$21.2M+37.3%
Operating income-$2.6M+38.7%
Net income-$3.5M+35.9%
EPS (diluted)-$0.11+42.1%

Balance sheet

See full
Cash & equivalents$20.8M+33.7%
Total debt$71.2M-3.2%
Total equity$18.5M+88.5%
Total assets$107.3M+11.4%

Cash flow

See full
Operating cash flow-$1.9M-12.8%
CapEx$30.0K-70.0%
Free cash flow-$2.0M-8.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$341.07M+69.6%
Enterprise value$391.48M+51.1%
P/S3.8×+1.1×

Profitability

See full
Gross margin78.1%+4.2pp
Operating margin-21.6%-4.8pp
Net margin-26.4%-5.8pp
FCF margin-18.3%-2.6pp

Returns & leverage

See full
Return on equity-169.3%-29.5pp
Debt / equity3.8×-3.6×
Current ratio4.9×-0.7×

FAQ

When did Neuropace, Inc. report Q3 2025 earnings?
Neuropace, Inc. (NPCE) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Neuropace, Inc.'s Q3 2025 revenue and EPS?
Neuropace, Inc. reported revenue of $27.4M and eps of $-0.11 for Q3 2025.
Did Neuropace, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $25.0M by $2.3M. EPS beat the consensus estimate of $-0.20 by $0.09.
How did Neuropace, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 29.9% from $21.1M a year earlier and eps grew 42.1% from $-0.19.
Where can I find Neuropace, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001528287-25-000030) and the 10-Q periodic report (0001528287-25-000032) directly on SEC EDGAR. The filing index links above go to sec.gov.